statistiche ricercatore

Continente	#
NA - Nord America	790
EU - Europa	417
AS - Asia	301
SA - Sud America	51
AF - Africa	16
Continente sconosciuto - Info sul continente non disponibili	2
OC - Oceania	2
Totale	1.579

Nazione	#
US - Stati Uniti d'America	768
IT - Italia	125
SG - Singapore	113
CN - Cina	70
DE - Germania	68
HK - Hong Kong	51
SE - Svezia	49
BR - Brasile	39
GB - Regno Unito	39
RU - Federazione Russa	23
FI - Finlandia	22
FR - Francia	18
VN - Vietnam	15
ES - Italia	13
CA - Canada	12
ID - Indonesia	11
NL - Olanda	10
BG - Bulgaria	9
LT - Lituania	9
PL - Polonia	9
IN - India	7
MX - Messico	7
AR - Argentina	6
IR - Iran	5
SI - Slovenia	5
TR - Turchia	5
ZA - Sudafrica	4
BE - Belgio	3
CH - Svizzera	3
CZ - Repubblica Ceca	3
JP - Giappone	3
MY - Malesia	3
SA - Arabia Saudita	3
SD - Sudan	3
AL - Albania	2
AU - Australia	2
BY - Bielorussia	2
CL - Cile	2
DO - Repubblica Dominicana	2
KR - Corea	2
MA - Marocco	2
MN - Mongolia	2
PE - Perù	2
PK - Pakistan	2
SN - Senegal	2
A2 - ???statistics.table.value.countryCode.A2???	1
AE - Emirati Arabi Uniti	1
BD - Bangladesh	1
CO - Colombia	1
DZ - Algeria	1
EG - Egitto	1
ET - Etiopia	1
EU - Europa	1
GA - Gabon	1
GE - Georgia	1
GH - Ghana	1
GR - Grecia	1
IE - Irlanda	1
KG - Kirghizistan	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LK - Sri Lanka	1
LV - Lettonia	1
PA - Panama	1
PS - Palestinian Territory	1
RO - Romania	1
UA - Ucraina	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.579

Nome	#
Herpes Simplex re-activation in patients with SARS-CoV2 pneumonia: a prospective observational study.	307
Circulating Mitochondrial DNA and Lipopolysaccharide-Binding Protein but Not Bacterial DNA Are Increased in Acute Human Immunodeficiency Virus Infection.	264
Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year Period	234
Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia	230
The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study	214
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)	191
Development of post-COVID-19 cardiovascular events: An analysis of clinical features and risk factors from a single hospital retrospective study	163
Totale	1.603

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	93	0	0	0	0	0	8	11	11	11	19	9	24
2021/2022	274	16	8	27	15	15	8	41	18	21	18	46	41
2022/2023	243	33	39	18	24	29	26	6	23	28	1	1	15
2023/2024	171	2	7	12	13	27	26	4	17	13	14	14	22
2024/2025	415	18	8	5	26	62	72	38	26	52	31	28	49
2025/2026	352	51	22	52	82	111	34	0	0	0	0	0	0
Totale													1.603